Posted by Michael Wonder on 05 Aug 2015

Agenda for the 23 July 2014 Transparency Commission meeting

Transparency Commission

The agenda for the 23 July 2014 Transparency Commission is now available. The Commission will consider the following new medicines and new uses for existing medicines:

  • Exenatide (Byetta) - new indication
  • Exenatide (Bydureon) - new formulation
  • Vildagliptin (Galvus) - new indication (use in combination with insulin)
  • Vildagliptin with metformin hydrochloride (Eucreas) - new indication (use in combination with insulin)
  • Ipilimumab (Yervoy) - new indication
  • Tocilizumab (RoActemra) - new indication
  • Canagliflozin hemihydrate (Invokana) - new medicine
  • Canagliflozin hemihydrate with metformin hydrochloride (VokanaMet) - New combination product
  • Saxagliptin hydrochloride (Onglyza) - new indication
  • Saxagliptin hydrochloride with metformin hydrochloride (Komboglyze) - new indication
  • Vildagliptin (Jalra/Icandra) - new indication
  • Vildagliptin (Galvus) - new indication (triple combination therapy)
  • Vildagliptin with metformin hydrochloride (Eucreas) - new indication (triple combination therapy)
Michael Wonder

Posted by:

Michael Wonder

Posted in: